Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion
Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion
Background: Malignant peritoneal adhesion is a common complication and prognostic factor of
 ovarian cancer and other primary abdominal tumors. The incidence of peritoneal adhesion in
 advanced primary peritoneal tumor is 32-56%, which has increased by more than 10 times in the
 recent decade. Malignant peritoneal adhesion is closely associated with the morbidity and
 mortality of malignant intestinal obstruction. The peritoneal adhesion may aggravates the
 abdominal symptoms and reduce quality of life. Further, the peritoneal adhesion may impede
 treatment of primary tumor, such as operation or chemotherapy, lead to a poor prognosis.

 Objective: This study aims to treat malignant peritoneal adhesion with the combination of
 antiangiogenic agent and chemotherapy, evaluate the efficacy and safety of intraperitoneal
 antiangiogenic agent plus chemotherapy. As explosive endpoints, we will examination the
 expression of VEGF-A in peritoneal cavity during the treatment.
Inclusion Criteria:

 1. Pathologically and radiologically confirmed stage IV or postoperative recurrence
 ovarian cancer.

 2. Age of 18-70, Karnofsky score higher than 80.

 3. No severe functional damage of major organ, normal liver and kidney function.

 4. Peritoneal adhesion. (1) peritoneal adhesions diagnosed by microlaparoscopy or
 abdominal operations, and classification according to Nair criteria is performed. (1)
 must be met. (2) Peritoneal adhesion symptoms, intermittent abdominal pain, abdominal
 distension, nausea and vomiting, hard to pass stools or gas; (3) Peritoneal adhesion
 signs，abdominal distension, abdominal tenderness, reduced or absent bowel sounds; (4)
 B ultrasound or CT or MRI show peritoneal adhesion or adhesion-related complications.

 Exclusion Criteria:

 1. Complete intestinal obstruction and suitable for surgery.

 2. Patients known to be allergic to bevacizumab or any of the components of the drug.

 3. Other ongoing anti-tumor treatment.

 4. Heart disease with significant clinical symptoms, such as: congestive heart failure,
 coronary heart disease with symptom, arrhythmia hardly be controlled by drugs,
 myocardial infarction in 6 months, or heart failure

 5. Active wound infection and a history of uncontrolled psychiatric illness.

 -